John Vavricka

Insider Reports History

Entity
Individual
Location
C/O Atea Pharmaceuticals, Inc., 125 Summer Street, Boston, MA
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by John Vavricka:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Atea Pharmaceuticals, Inc. Chief Commercial Officer Common Stock 82.5K $317K $3.84 Jan 31, 2024 Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust
Atea Pharmaceuticals, Inc. Chief Commercial Officer Restricted Stock Units 66.7K $256K $3.84 Jan 31, 2024 Direct
Atea Pharmaceuticals, Inc. Chief Commercial Officer Common Stock 21.5K $82.7K $3.84 Feb 1, 2024 Direct
Atea Pharmaceuticals, Inc. Chief Commercial Officer Stock Option (Right to Buy) 133K Jan 31, 2024 Direct

Insider Reports Filed by John Vavricka

Symbol Company Period Transactions Value $ Form Type Date Filed Role
AVIR Atea Pharmaceuticals, Inc. Jan 31, 2024 4 -$45.4K 4 Feb 2, 2024 Chief Commercial Officer
AVIR Atea Pharmaceuticals, Inc. Jan 31, 2023 2 $0 4 Feb 2, 2023 Chief Commercial Officer
AVIR Atea Pharmaceuticals, Inc. Jan 31, 2022 1 $0 4 Feb 2, 2022 Chief Commercial Officer